Eylea and Pregnancy
When Eylea (aflibercept) was given intravenously to pregnant rabbits in high doses, it increased the risk for birth defects. However, it is unknown if the medication would cause the same effects in humans, especially when low doses are used. If you are pregnant or thinking of becoming pregnant, talk to your healthcare provider before receiving this medication.
Can Pregnant Women Receive Eylea?Eylea™ (aflibercept) is a prescription medication approved for the treatment of age-related macular degeneration and macular edema due to central retinal vein occlusion. This medicine may not be safe for use during pregnancy. Animal studies of Eylea suggest that it may cause problems.
What Is Pregnancy Category C?Eylea is classified as a pregnancy Category C drug. The U.S. Food and Drug Administration (FDA) uses a category system to classify the possible risks to a fetus when a specific medicine is taken during pregnancy. Pregnancy Category C is given to medicines that have not been adequately studied in pregnant humans but have caused fetal harm in animal studies.
In addition, medicines that have not been studied in any pregnant women or animals are automatically given a pregnancy Category C rating.
When given to pregnant rabbits intravenously at very high doses (up to 2,900 times the exposure from the typical dose in humans), Eylea increased the risk for a variety of birth defects. It is unknown if the low doses used in humans could cause any problems. Notably, Eylea binds to and inhibits placental growth factor (PGF), a protein that may be important in pregnancy. It is unknown how Eylea's actions on PGF might affect a developing pregnancy.